Baldock (GB)
{name}
{subtitle}
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~8 mi. (Stevenage, United Kingdom, +159 more cities)
facility
Lister Hospital ( Site 0715)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~8 mi. (Stevenage, United Kingdom, +163 more cities)
facility
Lister Hospital ( Site 0739)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.
city
~8 mi. (Stevenage, United Kingdom, +137 more cities)
facility
Local Institution
condition
Bladder Urothelial Carcinoma
drug
bempegaldesleukin, +2 more drugs
drug type
immunotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~26 mi. (Cambridge, United Kingdom, +226 more cities)
facility
Cambridge University Hospitals NHS Trust ( Site 0540)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~26 mi. (Cambridge, United Kingdom, +199 more cities)
facility
Cambridge University Hospitals NHS Trust ( Site 0755)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
city
~26 mi. (Cambridge, United Kingdom, +126 more cities)
facility
Cambridge University Hospitals NHS Trust ( Site 0477)
condition
Adenocarcinoma of the Gastroesophageal Junction, +1 more condition
drug
FOLFOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer
city
~26 mi. (Cambridge, United Kingdom)
facility
Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
biomarker
BRCA1 Loss, +6 more biomarkers
condition
Breast Carcinoma
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type